Shuiniujiao Dihuang Decoction With Variation for the Treatment of Psoriasis

Recruiting Phase 2 Interventional Study
Psoriasis Vulgaris
Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 – 75
Sex
Any
Trial phase
Phase 2
Study type
Interventional
Purpose
Treatment
Participants needed
58 (estimated)
Sponsor
Chinese University of Hong Kong · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
Psoriasis is an inflammatory skin disease with huge negative impact on the quality of life of the patients, and has an overall prevalence of 2% to 3% in the general population. Plaques psoriasis is the most common type of the disease and presents red, well demarcated, and silvery plaques mainly localized in the umbilical and lumbosacral area as well as in the elbows, knees, and scalp. Currently, …
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Mild to moderate chronic plaque psoriasis (PASI score 3 to 12). * Willingness to give informed consent. Exclusion Criteria: * Pustular or generalized erythrodermic psoriasis. * Psoriatic arthritis with syndrome of spleen-kidney yang deficiency according to Chinese medicine t…
Contacts

Zhixiu LIN, PhD

852-3943 6347

linzx@cuhk.edu.hk

CONTACT

Tak Yee CHOW, MSc

852-2873 3075

cmtychow@cuhk.edu.hk

CONTACT